Malaysian Drug Firms Seek Patents Court

6 April 1997

The Malaysian drug industry organization, the MPTMA, has called for thecreation of special courts to hear drug patent-related issues, in order to ensure the prompt sentencing of offenders and adequate attention to the issues.

The MPTMA said that strict enforcement was needed to prevent patent infringement and argued that the maximum limit, currently five versions, allowed on the number of generic copies marketed in Malaysia should be abolished to allow a free market economy in line with the General Agreement on Tariffs and Trade. Both imported and locally-made generics should be allowed to compete freely with each other in the local market.

Also, the MPTMA wants the government to remove import duties on diagnostic strips for diabetes screening as soon as possible in order to control the cost. The current 10% tax imposed on cif items in the 1997 budget would result in a price hike, the MPTMA argues, which would have to be passed on to the consumer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight